US 7,482,320 B2
	Modulation of smooth muscle cell proliferation
Jeffrey C. Geesin, Doylestone, Pa. (US); Anna Gosiewska, Skillman, N.J. (US); Jean Xu, Hillsborough, N.J. (US); Robert Gordon, Ixworth (United Kingdom); Jeff Yon, Ely (United Kingdom); Sridevi Naidu Dhanaraj, Raritan, N.J. (US); and Ian Harris, Belle Mead, N.J. (US)
Assigned to Janssen Pharmaceutica N.V., Beerse (Belgium)
Appl. No. 10/471,221 PCT Filed Mar. 07, 2002, PCT No. PCT/EP02/02616 § 371(c)(1), (2), (4) Date Sep. 05, 2003, PCT Pub. No. WO02/072127, PCT Pub. Date Sep. 19, 2002.
Claims priority of provisional application 60/274901, filed on Mar. 09, 2001.
Prior Publication US 2004/0142886 A1, Jul. 22, 2004
Int. Cl. A61K 38/18 (2006.01); C07K 14/475 (2006.01)

U.S. Cl. 514—12  [514/2; 530/399]

2 Claims

1. A method of stimulating smooth muscle cell proliferation in tissues or organs and tissue repair in a subject comprising administering to said subject an amount of a CUB domain of VEGF-X polypeptide consisting essentially of the sequence from position 40 to 150 of the amino acid sequence depicted in SEQ ID NO: 7 or a polypeptide encompassing conservative amino acid changes thereof, in sufficient concentration to stimulate smooth muscle cell proliferation, wherein conservative amino acid changes include replacement of one or more amino acids of SEQ ID NO: 7 which do not affect the function of SEQ ID NO:7; and wherein the conservative amino acid changes result in a polypeptide having at least 95% amino acid homology to the amino acid sequence depicted in SEQ ID NO:7.